SINO BIOPHARM (01177): "Lidocaine Transdermal Patch" approved for market listing

SINO BIOPHARM (01177) announced that the group's developed "Rivastigmine Transdermal Patch" (brand name: Debai Tai) has obtained approval for listing from the China National Medical Products Administration, for the treatment of symptoms of mild to moderate Alzheimer's disease. This is the first domestically approved Rivastigmine Transdermal Patch. Rivastigmine is a cholinesterase inhibitor used to treat Alzheimer's disease. Acetylcholine is an important neurotransmitter that transmits information between neurons and plays a key role in brain areas related to memory and learning. Rivastigmine inhibits the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), reducing the degradation of acetylcholine, thereby increasing the levels of acetylcholine in the central nervous system and improving cognitive function in patients. The Rivastigmine Transdermal Patch can achieve continuous and stable drug release over a long period of time, maintaining stable blood drug concentrations in patients, reducing side effects and fluctuations in drug efficacy caused by fluctuations in drug concentrations. In addition, transdermal administration improves patient compliance, simplifies drug management, and is suitable for patients who are asleep, unresponsive, or unable to swallow oral medications, providing a more comfortable treatment option for patients. Alzheimer's disease (AD) is a progressive degenerative neurological disease with insidious onset, and is a major cause of dementia in the elderly. As the disease progresses, patients' cognitive function deteriorates gradually, affecting daily life and social interactions. Statistics show that there are approximately 50 million dementia patients worldwide, of which 60-70% have Alzheimer's disease. In 2021, there were nearly 17 million cases of Alzheimer's disease and other forms of dementia in China. With the aging population, the incidence of Alzheimer's disease is increasing year by year, potentially bringing a heavy burden on society's medical and elderly care resources. The group has rich experience in the research and development of patches and production, and is a leading modern transdermal patch research and industrialization base in China. The Rivastigmine Transdermal Patch is another important variety hatched from the group's patch platform. Adhering to the mission of "improving quality of life and upholding the dignity of life," the group is committed to helping alleviate the burden on patients and their families, using health technology to warm more lives.